Related references
Note: Only part of the references are listed.Cell adhesion molecule 1 is a new osteoblastic cell adhesion molecule and a diagnostic marker for osteosarcoma
Takao Inoue et al.
LIFE SCIENCES (2013)
A cohort study of the prognostic and treatment predictive value of SATB2 expression in colorectal cancer
J. Eberhard et al.
BRITISH JOURNAL OF CANCER (2012)
Regulators of skeletal development: a cluster analysis of 206 bone tumors reveals diagnostically useful markers
Andrew E. Horvai et al.
MODERN PATHOLOGY (2012)
SATB2 in Combination With Cytokeratin 20 Identifies Over 95% of all Colorectal Carcinomas
Kristina Magnusson et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2011)
Appraising the Current Role of Chemotherapy for the Treatment of Sarcoma
David R. D'Adamo
SEMINARS IN ONCOLOGY (2011)
Plasma membrane proteomic analysis of human osteosarcoma and osteoblastic cells: revealing NDRG1 as a marker for osteosarcoma
Yingqi Hua et al.
TUMOR BIOLOGY (2011)
Comparative proteomic analysis of plasma membrane proteins between human osteosarcoma and normal osteoblastic cell lines
Zhiyu Zhang et al.
BMC CANCER (2010)
Use of chemotherapy for patients with bone and soft-tissue sarcomas
R. WESOLOWSKI et al.
CLEVELAND CLINIC JOURNAL OF MEDICINE (2010)
A Cross-Species Analysis of Satb2 Expression Suggests Deep Conservation Across Vertebrate Lineages
Kelly Sheehan-Rooney et al.
DEVELOPMENTAL DYNAMICS (2010)
Expression of master regulatory genes controlling skeletal development in benign cartilage and bone forming tumors
Jane Y. Dancer et al.
HUMAN PATHOLOGY (2010)
4.5 Mb microdeletion in chromosome band 2q33.1 associated with learning disability and cleft palate
Jill Urquhart et al.
EUROPEAN JOURNAL OF MEDICAL GENETICS (2009)
Small Deletions of SATB2 Cause Some of the Clinical Features of the 2q33.1 Microdeletion Syndrome
Jill A. Rosenfeld et al.
PLOS ONE (2009)
Histogenetic characterization of giant cell tumor of bone
Manuela Salerno et al.
CLINICAL ORTHOPAEDICS AND RELATED RESEARCH (2008)
Dedifferentiated chondrosarcoma: Prognostic factors and outcome from a European group
Robert J. Grimer et al.
EUROPEAN JOURNAL OF CANCER (2007)
Heterozygous nonsense mutation SATB2 associated with cleft palate, osteoporosis, and cognitive defects
Petcharat Leoyklang et al.
HUMAN MUTATION (2007)
Signaling and transcriptional regulation in osteoblast commitment and differentiation
Wei Huang et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2007)
SATB2 is a multifunctional determinant of craniofacial patterning and osteoblast differentiation
Gergana Dobreva et al.
CELL (2006)
Osteosarcoma: A randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate
PA Meyers et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Dedifferentiated chondrosarcoma: The role of chemotherapy with updated outcomes
ID Dickey et al.
JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME (2004)
Identification of SATB2 as the cleft palate gene on 2q32-q33
DR FitzPatrick et al.
HUMAN MOLECULAR GENETICS (2003)
Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone
HE Grier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)